The role of incretin receptor agonists in the treatment of obesity.
dual co‐agonists
incretins
obesity
semaglutide
tirzepatide
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
revised:
28
06
2024
received:
03
05
2024
accepted:
29
06
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Obesity and its associated metabolic conditions have become a significant global health problem in recent years, with many people living with obesity fulfilling criteria for pharmacological treatment. The development of the glucagon-like peptide-1 receptor agonists for chronic weight management has triggered new interest in the incretins and other hormones as targets for obesity, and investigations into dual and triple co-agonists. The objective of this narrative review was to summarize the available data on approved and emerging incretin-based agents for the treatment of obesity. In clinical trials of currently available agents in people with overweight or obesity, weight loss of between 6% and 21% of baseline body weight has been observed, with between 23% and 94% of participants achieving 10% or higher weight loss, depending on the study and the agent used. Favourable outcomes have also been seen with regard to cardiovascular risk and outcomes, diabetes prevention, metabolic dysfunction-associated steatotic liver disease/steatohepatitis and prevention of weight regain after metabolic surgery. Limitations associated with these agents include high costs, the potential for weight regain once treatment is stopped, the potential loss of lean body mass and gastrointestinal adverse events; potential issues with respect to gallbladder and biliary diseases require further investigation. Many dual and triple co-agonists are still in development, and more data are needed to assess the efficacy, safety and tolerability of these emerging therapies versus the established incretin-based therapies; however, data are promising, and further results are eagerly awaited.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Clinical Research Services, Grenadiesrstrasse 1, 68167 Mannheim, Germany
Informations de copyright
© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
World Health Organization. Obesity and Overweight. 2024 Accessed June 5, 2024. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Haam JH, Kim BT, Kim EM, et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of obesity. J Obes Metab Syndr. 2023;32(2):121‐129.
Ogawa W, Hirota Y, Miyazaki S, et al. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2024;71(3):223‐231.
World Obesity Federation. World Obesity Atlas. 2023 Accessed October 2, 2023. https://www.worldobesity.org/resources/resource‐library/world‐obesity‐atlas‐2023
Ogawa W, Miyazaki S. Diagnosis criteria for obesity and obesity disease. Health Eval Promot. 2015;42(2):301‐306.
Pan WH, Yeh WT. How to define obesity? Evidence‐based multiple action points for public awareness, screening, and treatment: an extension of Asian‐Pacific recommendations. Asia Pac J Clin Nutr. 2008;17(3):370‐374.
Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315.
Lauterbach MA, Wunderlich FT. Macrophage function in obesity‐induced inflammation and insulin resistance. Pflugers Arch. 2017;469(3–4):385‐396.
Zhang T, Chen J, Tang X, Luo Q, Xu D, Yu B. Interaction between adipocytes and high‐density lipoprotein:new insights into the mechanism of obesity‐induced dyslipidemia and atherosclerosis. Lipids Health Dis. 2019;18(1):223.
Fantin F, Giani A, Zoico E, Rossi AP, Mazzali G, Zamboni M. Weight loss and hypertension in obese subjects. Nutrients. 2019;11(7):1667.
Quek J, Chan KE, Wong ZY, et al. Global prevalence of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20‐30.
Powell‐Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984‐e1010.
Pandey A, Patel KV, Vaduganathan M, et al. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. JACC Heart Fail. 2018;6(12):975‐982.
Durrer Schutz D, Busetto L, Dicker D, et al. European practical and patient‐centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12(1):40‐66.
Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):S1‐S203.
Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A. Management of overweight and obesity in primary care—a systematic overview of international evidence‐based guidelines. Obes Rev. 2019;20(9):1218‐1230.
Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402‐424.
US FDA. FDA approves new drug treatment for chronic weight management, first since 2014. 2021 Accessed October 12, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.
European Medicines Agency. Wegovy. 2022 Accessed October 12, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy.
Nordisk N. VICTOZA® (liraglutide) injection, for subcutaneous use. Prescribing information. 2017 Accessed October 3, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf.
Nordisk N. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing information. 2017 Accessed June 5, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf.
Eli Lilly and Company. MOUNJARO® (tirzepatide) injection, for subcutaneous use. Prescribing information. 2023 Accessed October 13, 2023. https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi.
Reuters. Lilly weight‐loss drug gets US, UK approval to rival Wegovy. 2023 Accessed November 21, 2023.https://www.reuters.com/business/healthcare‐pharmaceuticals/us‐fda‐approves‐lillys‐weight‐loss‐drug‐2023‐11‐08/.
US FDA. ZEPBOUND™ (tirzepatide) injection, for subcutaneous use. Prescribing information. 2023 Accessed January 12, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf.
Eli Lilly and Company. Mounjaro® (tirzepatide). Summary of product characteristics. 2022 Accessed February 28, 2024.https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf.
Chia CW, Egan JM. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020;1461(1):104‐126.
Muscelli E, Mari A, Natali A, et al. Impact of incretin hormones on beta‐cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab. 2006;291(6):E1144‐E1150.
Andreasen CR, Andersen A, Vilsboll T. The future of incretins in the treatment of obesity and non‐alcoholic fatty liver disease. Diabetologia. 2023;66(10):1846‐1858.
Imbernon M, Saponaro C, Helms HCC, et al. Tanycytes control hypothalamic liraglutide uptake and its anti‐obesity actions. Cell Metab. 2022;34(7):1054‐1063.e1057.
van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon‐like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1‐T16.
Baggio LL, Drucker DJ. Glucagon‐like peptide‐1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223‐4226.
Bakker W, Imbernon M, Salinas CG, et al. Acute changes in systemic glycemia gate access and action of GLP‐1R agonist on brain structures controlling energy homeostasis. Cell Rep. 2022;41(8):111698.
Liskiewicz A, Khalil A, Liskiewicz D, et al. Glucose‐dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nat Metab. 2023;5(12):2075‐2085.
Zhang Q, Delessa CT, Augustin R, et al. The glucose‐dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS‐GIPR signaling. Cell Metab. 2021;33(4):833‐844 e835.
Del Prato S, Gallwitz B, Holst JJ, Meier JJ. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obes Rev. 2022;23(2):e13372.
Hayes MR, Borner T, De Jonghe BC. The role of GIP in the regulation of GLP‐1 satiety and nausea. Diabetes. 2021;70(9):1956‐1961.
Salem V, Izzi‐Engbeaya C, Coello C, et al. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016;18(1):72‐81.
Al‐Massadi O, Ferno J, Dieguez C, Nogueiras R, Quinones M. Glucagon control on food intake and energy balance. Int J Mol Sci. 2019;20(16):3905.
Clemmensen C, Finan B, Muller TD, DiMarchi RD, Tschop MH, Hofmann SM. Emerging hormonal‐based combination pharmacotherapies for the treatment of metabolic diseases. Nat Rev Endocrinol. 2019;15(2):90‐104.
Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol. 2012;215(3):335‐346.
Andersen DB, Holst JJ. Peptides in the regulation of glucagon secretion. Peptides. 2022;148:170683.
Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998‐1008.
Milliken BT, Elfers C, Chepurny OG, et al. Design and evaluation of peptide dual‐agonists of GLP‐1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis. J Med Chem. 2021;64(2):1127‐1138.
Steinert RE, Feinle‐Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP‐1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411‐463.
Pi‐Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11‐22.
Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36(10):3276‐3282.
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet. 2017;389(10077):1399‐1409.
Foghsgaard S, Vedtofte L, Andersen ES, et al. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: a 52‐week randomized controlled clinical trial. Diabetes Obes Metab. 2023;26:201‐214.
Kelly AS, Auerbach P, Barrientos‐Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117‐2128.
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687‐699.
Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085‐1093.
Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719‐1730.
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low‐calorie‐diet‐induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443‐1451.
Mok J, Adeleke MO, Brown A, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI‐OPTIMISE randomized clinical trial. JAMA Surg. 2023;158(10):1003‐1011.
Miras AD, Perez‐Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549‐559.
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non‐alcoholic steatohepatitis (LEAN): a multicentre, double‐blind, randomised, placebo‐controlled phase 2 study. Lancet. 2016;387(10019):679‐690.
Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311‐322.
Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20(3):734‐739.
Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403‐1413.
Wilding JPH, Batterham RL, Calanna S, et al. Once‐weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989‐1002.
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138‐150.
Weghuber D, Barrett T, Barrientos‐Perez M, et al. Once‐weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245‐2257.
Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3 trial. Lancet. 2021;397(10278):971‐984.
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193‐206.
Jensen AB, Renström F, Aczél S, et al. Efficacy of the glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017‐1025.
Lautenbach A, Kantowski T, Wagner J, Mann O, Stoll F, Aberle J. Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post‐bariatric treatment failure. Clin Obes. 2023;13(5):e12593.
Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280‐1289.
Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non‐alcoholic steatohepatitis‐related cirrhosis: a randomised, placebo‐controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511‐522.
Newsome PN, Buchholtz K, Cusi K, et al. A placebo‐controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113‐1124.
Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468‐478.
Perreault L, Davies M, Frias JP, et al. Changes in glucose metabolism and glycemic status with once‐weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program. Diabetes Care. 2022;45(10):2396‐2405.
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553‐1564.
Lincoff AM, Brown‐Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221‐2232.
Borlaug BA, Kitzman DW, Davies MJ, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP‐HFpEF trial. Nat Med. 2023;29(9):2358‐2365.
Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069‐1084.
Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(5):979‐994.
Singh G, Krauthamer M, Bjalme‐Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5‐13.
Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2023;402(10403):705‐719.
Wharton S, Blevins T, Connery L, et al. Daily oral GLP‐1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877‐888.
Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose–response, phase 2 study. Lancet. 2023;402(10400):472‐483.
Nordisk N. RYBELSUS (semaglutide) tablets, for oral use. Prescribing information. 2019 Accessed March 28, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf.
Malik F, Li Z. Non‐peptide agonists and positive allosteric modulators of glucagon‐like peptide‐1 receptors: alternative approaches for treatment of type 2 diabetes. Br J Pharmacol. 2022;179(4):511‐525.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205‐216.
Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT‐3 phase 3 trial. Nat Med. 2023;29(11):2909‐2918.
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT‐4 randomized clinical trial. JAMA. 2024;331(1):38‐48.
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT‐2): a double‐blind, randomised, multicentre, placebo‐controlled, phase 3 trial. Lancet. 2023;402(10402):613‐626.
Hankosky ER, Wang H, Neff LM, et al. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: post hoc analysis of the SURMOUNT‐1 trial. Diabetes Obes Metab. 2023;25(12):3748‐3756.
Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP‐1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS‐1): a double‐blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143‐155.
Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS‐5 randomized clinical trial. JAMA. 2022;327(6):534‐545.
Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add‐on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J‐combo): a multicentre, randomised, open‐label, parallel‐group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):634‐644.
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503‐515.
Ludvik B, Giorgino F, Jodar E, et al. Once‐weekly tirzepatide versus once‐daily insulin degludec as add‐on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS‐3): a randomised, open‐label, parallel‐group, phase 3 trial. Lancet. 2021;398(10300):583‐598.
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS‐4): a randomised, open‐label, parallel‐group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811‐1824.
Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono): a double‐blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623‐633.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Comparative effectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the US: a real‐world evidence study. medRxiv. 2023. doi:10.1101/2023.11.21.23298775
Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS‐3 MRI): a substudy of the randomised, open‐label, parallel‐group, phase 3 SURPASS‐3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393‐406.
Eli Lilly and Company. Lilly reports strong fourth‐quarter 2023 financial results and provides 2024 guidance. 2024; Accessed June 4, 2024.https://investor.lilly.com/node/50281/pdf.
Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP‐1 receptor agonist Tirzepatide on biomarkers of nonalcoholic Steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352‐1355.
Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre‐specified meta‐analysis. Nat Med. 2022;28(3):591‐598.
Frias JP, Bastyr EJ 3rd, Vignati L, et al. The sustained effects of a dual GIP/GLP‐1 receptor agonist, NNC0090‐2746, in patients with type 2 diabetes. Cell Metab. 2017;26(2):343‐352 e342.
Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP‐1 co‐agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749‐757.
Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721‐766.
Pocai A, Carrington PE, Adams JR, et al. Glucagon‐like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258‐2266.
Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696‐4701.
Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double‐blind, randomized, controlled trial. Diabetes. 2005;54(8):2390‐2395.
Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP‐1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo‐controlled, multiple‐ascending‐dose phase 1b trial. EClinicalMedicine. 2022;54:101691.
Ji L, Jiang H, An P, et al. IBI362 (LY3305677), a weekly‐dose GLP‐1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo‐controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021;39:101088.
Jiang H, Pang S, Zhang Y, et al. A phase 1b randomised controlled trial of a glucagon‐like peptide‐1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613.
Zhang B, Cheng Z, Chen J, et al. Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled phase 2 trial. Diabetes Car. 2024;47(1):160‐168.
Asano M, Sekikawa A, Sugeno M, Matsuoka O, Robertson D, Hansen L. Safety/tolerability, efficacy and pharmacokinetics of 600‐mug cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m(2) or higher: a phase I, randomized, double‐blind, placebo‐controlled study. Diabetes Obes Meta. 2023;25(8):2290‐2299.
Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54‐week randomized phase 2b study. Diabetes Care. 2021;44(6):1433‐1442.
Parker VER, Robertson D, Wang T, et al. Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon‐like peptide‐1 and glucagon agonist. J Clin Endocrinol Metab. 2020;105(3):803‐820.
Technology P. AZ to terminate once‐daily cotadutide program to focus on weekly GLP‐1RA co‐agonist. 2023; Accessed November 21, 2023.https://www.pharmaceutical-technology.com/analyst-comment/az-terminate-cotadutide-coagonist/.
Romero‐Gomez M, Lawitz E, Shankar RR, et al. A phase IIa active‐comparator‐controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non‐alcoholic fatty liver disease. J Hepatol. 2023;79(4):888‐897.
Alba M, Yee J, Frustaci ME, Samtani MN, Fleck P. Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose‐ranging study. Clin Obes. 2021;11(2):e12432.
Di Prospero NA, Yee J, Frustaci ME, Samtani MN, Alba M, Fleck P. Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose‐ranging study. Clin Obes. 2021;11(2):e12433.
Zimmermann T, Thomas L, Baader‐Pagler T, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP‐1R dual agonist with robust anti‐obesity efficacy. Mol Metab. 2022;66:101633.
Jungnik A, Arrubla Martinez J, Plum‐Morschel L, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906. Diabetes Obes Metab. 2023;25(4):1011‐1023.
Yazawa R, Ishida M, Balavarca Y, Hennige AM. A randomized phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes Obes Metab. 2023;25(7):1973‐1984.
Le Roux C, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. 51‐OR: a phase 2, randomized, double‐blind, placebo‐controlled, dose‐finding study of BI 456906 in people with overweight/obesity. Diabete. 2023;72(Supplement):51‐OR.
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis [media release] [press release]. 26 February 2024.
Corbin KD, Carnero EA, Allerton TD, et al. Glucagon‐like peptide‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial. Obesity (Silver Spring). 2023;31(2):350‐362.
Lau DCW, Erichsen L, Francisco AM, et al. Once‐weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double‐blind, placebo‐controlled and active‐controlled, dose‐finding phase 2 trial. Lancet. 2021;398(10317):2160‐2172.
Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co‐administered once‐weekly cagrilintide 2·4 mg with once‐weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double‐blind, active‐controlled, phase 2 trial. Lancet. 2023;402(10403):720‐730.
Gydesen S, Andreassen KV, Hjuler ST, Hellgren LI, Karsdal MA, Henriksen K. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP‐089 through dose escalation and combination with a GLP‐1 analog. Am J Physiol Endocrinol Metab. 2017;313(5):E598‐E607.
Larsen AT, Gydesen S, Sonne N, Karsdal MA, Henriksen K. The dual amylin and calcitonin receptor agonist KBP‐089 and the GLP‐1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. BMC Endocr Disord. 2021;21(1):10.
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP‐1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234‐1247. e1239.
Jastreboff AM, Kaplan LM, Frias JP, et al. Triple‐hormone‐receptor agonist retatrutide for obesity – a phase 2 trial. N Engl J Med. 2023;389(6):514‐526.
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP‐1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double‐blind, placebo and active‐controlled, parallel‐group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529‐544.
Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction‐associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:1–12.
Brouwers B, Rao G, Tang Y, Rodríguez Á, Glass LC, Hartman ML. Incretin‐based investigational therapies for the treatment of MASLD/MASH. Diabetes Res Clin Pract. 2024;211:111675.
Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP‐1/GIP/GCG receptor triagonist. Cell Metab. 2022;34(1):59‐74. e10.
Abdelmalek MF, Suzuki A, Sanchez W, et al. A phase 2, adaptive randomized, double‐blind, placebo‐controlled, multicenter, 52‐week study of HM15211 in patients with biopsy‐confirmed non‐alcoholic steatohepatitis – study design and rationale of HM‐TRIA‐201 study. Contemp Clin Trials. 2023;130:107176.
Karagiannis T, Bekiari E, Tsapas A. Socioeconomic aspects of incretin‐based therapy. Diabetologia. 2023;66(10):1859‐1868.
McCrimmon RJ, Catarig AM, Frias JP, et al. Effects of once‐weekly semaglutide vs once‐daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63(3):473‐485.
Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998‐1004.
Kremer D, Sizoo D, Bakker SJL, van Beek AP. Obesity management strategies should cut fat, not muscle. Int J Obes (Lond). 2024;48:1039‐1040. doi:10.1038/s41366‐024‐01502‐w
Nunn E, Jaiswal N, Gavin M, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP‐1 receptor agonism. Mol Metab. 2024;80:101880.
Deng Y, Park A, Zhu L, Xie W, Pan CQ. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Ther Adv Chronic Dis. 2022;13:20406223221108064.
Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP‐1 receptor agonist tirzepatide: a systematic review and meta‐analysis. Diabetologia. 2022;65(8):1251‐1261.
Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y. The efficacy and safety of liraglutide in the obese, non‐diabetic individuals: a systematic review and meta‐analysis. Afr Health Sci. 2019;19(3):2591‐2599.
Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking GLP‐1 receptor agonists prior to endoscopy: communication. Clin Gastroenterol Hepatol. 2024;22(4):705‐707.
Gamble JM, Chibrikov E, Midodzi WK, Twells LK, Majumdar SR. Examining the risk of depression or self‐harm associated with incretin‐based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK clinical practice research datalink. BMJ Open. 2018;8(10):e023830.
US FDA. FDA Drug Safety Communication: Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity 2023. Accessed March 4, 2024.https://www.fda.gov/drugs/drug‐safety‐and‐availability/update‐fdas‐ongoing‐evaluation‐reports‐suicidal‐thoughts‐or‐actions‐patients‐taking‐certain‐type.
Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22(4):699‐704.
Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: a systematic review and meta‐analysis. Diabetes Metab Syndr. 2023;17(9):102834.
He L, Wang J, Ping F, et al. Association of glucagon‐like peptide‐1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta‐analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513‐519.
Yoshida Y, Joshi P, Barri S, et al. Progression of retinopathy with glucagon‐like peptide‐1 receptor agonists with cardiovascular benefits in type 2 diabetes ‐ a systematic review and meta‐analysis. J Diabetes Complications. 2022;36(8):108255.
Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes. 2024;48:1–19. doi:10.1038/s41366‐024‐01473‐y
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414‐1425.
Garvey WT, Batterham RL, Bhatta M, et al. Two‐year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083‐2091.